The prognosis of upper urinary tract urothelial carcinoma (UTUC) is associated with tumour grade (G) and stage. Despite preoperative risk stratification and radical treatment, recurrence and progression are common.
Thus, prognostic and monitoring biomarkers are needed. This feasibility study aimed to investigate if targeted analyses on circulating tumour DNA (ctDNA) in plasma could identify tumour-specific gene variants, and thus have potential for further evaluation as a biomarker in UTUC.
Nine UTUC patients with genetically characterised tumours were included in this prospective pilot study. Two tumour-specific variants were chosen for targeted analyses with multiplex droplet digital PCR on cell-free DNA (cfDNA) from plasma at diagnosis or from recurrence.
Of six patients with diagnostic plasma samples, ctDNA was detected in four with G2 or G3 tumours and tumours > 300m2 in size. Three of these patients progressed in their disease and the fourth had the largest G3 tumour at sampling. In contrast, the two patients with undetectable ctDNA in diagnostic plasma had a G1 tumour and G3 carcinoma in situ (CIS), respectively. The patient with G3 CIS had detectable ctDNA later during follow-up and progressed thereafter with aggressive intravesical recurrence and CT-scan-verified CIS progression in the upper urinary tract. In three patients with small recurrent G1 or G2 tumours, none had detectable ctDNA in plasma and all were progression free.
Our early findings demonstrate that ctDNA in plasma can be detected by targeted analysis in patients with UTUC. However, further studies are needed to determine its role as a potential biomarker.
World journal of urology. 2023 Sep 18 [Epub ahead of print]
Ninni Mu, Cecilia Jylhä, Tomas Axelsson, Filip Sydén, Marianne Brehmer, Emma Tham
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden., Division of Urology, Danderyd Hospital, Stockholm, Sweden., Department of Urology, Stockholm South General Hospital, Stockholm, Sweden., Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. emma.tham@ki.se.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/37721600